PureTech Health plc (NASDAQ: PRTC, LSE: PRTC) announced positive results from a Phase 1b clinical trial of LYT-200, an anti-galectin-9 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE